

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 May 2020 (28.05.2020)



(10) International Publication Number
WO 2020/106647 A3

(51) International Patent Classification:

A61K 31/555 (2006.01) A61P 35/00 (2006.01)
A61K 31/506 (2006.01) A61K 39/395 (2006.01)
A61K 31/519 (2006.01) C07K 16/28 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2019/062064

(22) International Filing Date:

18 November 2019 (18.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/769,355	19 November 2018 (19.11.2018)	US
62/821,376	20 March 2019 (20.03.2019)	US
62/865,819	24 June 2019 (24.06.2019)	US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **LIPFORD, James Russell**; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, CA 91320-1799 (US). **CANON, Jude Robert**; One Amgen Center Drive, Legal Dept - Patent Operations

MS 28-5-A, Thousand Oaks, CA 91320-1799 (US). **SAIKI, Anne Y.**; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, CA 91320-1799 (US). **REX, Karen Louise**; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, CA 91320-1799 (US).



(74) Agent: **REIDY, Joseph F.**; One Amgen Center Drive, Legal Dept - Patent Operations MS 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: COMBINATION THERAPY INCLUDING A KRAS^{G12C} INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS

FIG. 45B



(I)

(57) Abstract: The present invention provides combination therapy that includes an KRAS^{G12C} inhibitor, such as (see Formula), or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRAS^{G12C} inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

WO 2020/106647 A3

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

26 November 2020 (26.11.2020)